about
HIV and its relationship to insulin resistance and lipid abnormalities.Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia.Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation.Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionEpidemiology of Cryptococcosis and Cryptococcal Meningitis in a Large Retrospective Cohort of Patients After Solid Organ TransplantationDiagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Prophylaxis of opportunistic infections.APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice.Switching effective antiretroviral therapy: a review.Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.Developing a human immunodeficiency virus/acquired immunodeficiency syndrome therapeutic research agenda for resource-limited countries: a consensus statement.Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia.Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapyEarly antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Recommendations for evaluation and management of bone disease in HIV.Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants.Whole-body proteolysis rate is elevated in HIV-associated insulin resistance.Hepatic steatosis and HIV infection.Clinical perspectives of emerging pathogens in bleeding disorders.Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center.Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence.Prevalence of hepatitis C virus infection among human immunodeficiency virus-1-infected pregnant women in Malawi: the BAN studyMetabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.Osteopenia and osteoporosis in HIV: pathogenesis and treatment.Class-sparing regimens for initial treatment of HIV-1 infection.Progenitor cell types in HIV-1 infection: bioactivity and emerging targets for treatment.Integrase inhibitors in the treatment of HIV-1 infection.Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.Osteoporosis and bone health in HIV.Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV.Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials.Vitamin D and calcium abnormalities in the HIV-infected population.HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development.Impact of Infectious Diseases Consultation on Mortality of Cryptococcal infection in Patients without HIV.Invasive Fungal Infections Secondary to Traumatic Injury.Comments on cochrane review on direct-acting antivirals for hepatitis C.
P50
Q30239101-5B505CC3-E3DE-4E42-B2F6-7DEAC0216F3EQ30372270-080FB1BA-35A2-41A3-8394-D291321DB742Q30452376-4D789F64-C739-4604-9097-A6A75774DCCEQ33325623-3D16DD8B-E7BA-453B-88F0-DDDB25501C46Q33628799-4CDB32F8-D5DF-4DE2-B658-FD548A5B72B8Q33629107-4BD7A18D-EE3C-440E-962B-CEB52B85AD22Q33770795-C01E26F3-7385-4AD0-A24D-D3BC49C8C8A0Q34020746-AE8DFB34-E414-43C3-BD92-41BD82A8D936Q34122368-76697940-BA58-41DE-B562-2435E6F30147Q34353493-C144FE37-B77A-4D20-AC9E-DB6A9132F7F0Q34532589-E26FFF7A-3BC9-4283-BC2E-5E26A15C22A4Q34985833-F405DD3D-5E00-44D5-B8F7-ABA2C4AE2831Q35002031-CEB25CB7-0677-45A2-97A2-B5E4DAD9B5CAQ35160767-72A3CD11-90EB-4193-8CC6-4762C563987BQ35193330-16D1866B-F1A2-4160-8EDB-32E3557A32FBQ35194049-13F94311-0BE3-4542-A738-020631C628F2Q35244295-A7C3A4DB-2374-4F67-ACB9-F03C2F70BD5FQ35451868-2E834588-08E9-4667-9E2C-2FCCAAB95364Q35542419-C80359B0-1A5B-4C65-AA1F-D22987FAE484Q35575238-E61F1691-3B7D-411F-8152-8C26FAC37FBCQ36179642-EDAC4E46-EFCB-4FDE-B5C3-45316E468587Q36374188-4440DD3C-DF26-4F97-8C23-7FEB317F124FQ36527174-8252DC27-9759-48A7-9ED8-D85F6AF9CE5DQ36640816-5001BAC8-30CD-4C1F-B60F-890081723D78Q36765488-56F7066C-FC3F-4905-9A9B-DEF6D7700B1EQ36839535-1721C7E7-4244-439D-9F66-B9E13F61414CQ37338133-D8AD3F1C-4BB7-4294-B6AF-A3F55C8D6D41Q37447325-BC0AF792-8C72-475D-83D1-D1B52E1DB02FQ37454026-2126B73A-4DB2-4831-82C3-EB881D1BD960Q37522565-6DD1D727-94A8-4AB7-A7C1-93A2A8C749F7Q37790212-A2288E30-1038-4116-89E4-50CAABEBB873Q37887890-B76CFA3E-0963-41E5-8EEA-88F458FF567AQ38009732-CCC84EF4-3C41-4B59-8344-C1039411731AQ38014630-5543CF97-7992-461D-81FB-A136D1FEA7DDQ38221722-6704D760-ED87-4DDF-AE46-27CBB022E656Q38244431-B4E081E2-0590-457A-AB5C-28AFCF2FC3D3Q38294983-82047E86-058A-4352-95E5-BDFE9DCF691EQ39121786-DC71716B-518B-4AA0-83FE-EE2EF7AA5CCAQ39433628-5176F8EA-2D1A-4B03-B03D-7D9398ED7F65Q39438394-45BBA78C-5692-48EB-8579-51D32BCE6166
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
William G Powderly
@ast
William G Powderly
@en
William G Powderly
@es
William G Powderly
@nl
type
label
William G Powderly
@ast
William G Powderly
@en
William G Powderly
@es
William G Powderly
@nl
prefLabel
William G Powderly
@ast
William G Powderly
@en
William G Powderly
@es
William G Powderly
@nl
P108
P106
P1153
7007053020
P2038
William_Powderly
P21
P2963
P31
P496
0000-0001-7808-3086